Overview

Growth hormone-releasing peptides (GHRPs) are synthetic hexapeptides and related compounds that mimic the endogenous ghrelin hormone at the GHS-R1a receptor. GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) and GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) were among the earliest characterised synthetic GHRPs and remain foundational reference compounds in growth hormone secretagogue research. Despite sharing the same primary receptor target, their pharmacological profiles diverge in clinically meaningful ways.

GHS-R1a Receptor Binding

Both GHRP-2 and GHRP-6 bind GHS-R1a with high affinity. Radioligand competition assays report IC50 values of approximately 0.3–1 nM for GHRP-2 and 2–5 nM for GHRP-6, indicating GHRP-2’s superior binding affinity at the primary receptor. GHS-R1a is a Gαq-coupled receptor; agonist binding triggers IP3 generation, intracellular Ca2+ release, and PKC activation in pituitary somatotroph cells, culminating in GH secretion.

In cell-based calcium flux assays using GHS-R1a-transfected HEK293 cells, GHRP-2 produces greater maximum calcium responses than GHRP-6 at equimolar concentrations, consistent with its higher binding affinity.

Cortisol and ACTH Co-Release

A key distinguishing feature is GHRP-2’s more pronounced stimulation of ACTH and cortisol release relative to GHRP-6. Studies in human subjects show GHRP-2 administered intravenously produces significant ACTH and cortisol elevation alongside GH release, an effect attributed to GHS-R1a activation in hypothalamic CRH neurons and direct pituitary corticotroph stimulation. GHRP-6 produces substantially less ACTH/cortisol co-stimulation at equivalent doses in comparative studies, making it a cleaner model compound for isolated somatotroph research.

For in vitro experiments specifically examining somatotroph biology in isolation, GHRP-6 is therefore often preferred to minimise confounding HPA axis activation in mixed pituitary cell cultures.

Prolactin Stimulation

GHRP-2 also exhibits greater prolactin-stimulating activity than GHRP-6, an effect mediated at least partially through dopaminergic pathways and direct lactotroph GHS-R1a activation. This is a relevant variable in research designs using mixed anterior pituitary cell populations where prolactin secretion is monitored as a readout.

Appetite and Orexigenic Activity

Peripheral GHS-R1a activation, particularly in hypothalamic arcuate nucleus NPY/AgRP neurons, drives orexigenic signalling. Both GHRP-2 and GHRP-6 activate this pathway, but GHRP-6 has historically been characterised as producing stronger acute appetite stimulation in animal studies, possibly related to differences in blood-brain barrier penetration and hypothalamic receptor pharmacology. This property makes GHRP-6 a commonly used tool compound in hypothalamic appetite research.

Cytoprotective and Non-Somatotropic Activity

GHS-R1a-independent cytoprotective effects have been described for both peptides. GHRP-2 has been studied in cardiac ischaemia-reperfusion models where it reduces apoptosis markers (cleaved caspase-3, cytochrome c release) in cardiomyocyte cultures independent of pituitary GH release. Similar cardioprotective observations exist for GHRP-6. These effects appear to involve a distinct, non-GHS-R1a receptor (sometimes termed CD36 or related scavenger receptors) though this remains an active area of mechanistic research.

Research Protocol Considerations

When designing experiments where isolated somatotroph GH secretion is the primary endpoint, GHRP-6’s lower cortisol and prolactin co-stimulation makes it a cleaner research tool. When studying the full spectrum of GHS-R1a signalling, including HPA axis effects, GHRP-2’s broader hormonal profile provides richer physiological modelling. Both are commonly combined with GHRH analogues (CJC-1295, sermorelin) to achieve synergistic GH secretion in research models.

For research use only. Not for human consumption. All Stackpure peptides carry a third-party COA confirming ≥99% purity by HPLC.